Research peptides
SS-31
Also known as Elamipretide
SS-31, better known as elamipretide and also called MTP-131, is a four-amino-acid Szeto-Schiller peptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. It homes in on the inner membrane of mitochondria. In September 2025 the FDA granted accelerated approval to elamipretide hydrochloride, sold as FORZINITY, for a single rare disease.
- Container
- Glass vial, crimp seal, flip-top cap
- Storage
- -20 °C, desiccated
- Paperwork
- Lot certificate (HPLC + mass spec) shown before you pay
Lot certificates
You’ll see American Peptides on the lab’s copy. They’re our supplier.
- 10 mg, lot SS31-10-0803: 99.77% purity (RP-HPLC), 10.44 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7584
- 30 mg, lot SS31-30-0803: 99.78% purity (RP-HPLC), 30.84 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7579
- 50 mg, lot SS31-50-0803: 99.75% purity (RP-HPLC), 50.90 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7590
Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.
What researchers study it for
- Muscle strength in people with Barth syndrome
- Muscle disease caused by mitochondrial defects
- Heart failure of the reduced-ejection-fraction type
- Macular degeneration linked to aging
- Cardiolipin and how mitochondria make energy
How it is thought to work
The peptide attaches to cardiolipin, a fat molecule that sits in the inner mitochondrial membrane, using both charge and water-repelling contacts. In bench experiments, that attachment keeps cardiolipin from turning cytochrome c into a peroxidase enzyme while letting cytochrome c keep ferrying electrons; researchers also saw cristae folds and oxidative phosphorylation stay intact. On the FDA label the drug is classed as a mitochondrial cardiolipin binder.
Where the research stands
Accelerated FDA approval for Barth syndrome. The approval for FORZINITY (NDA 215244) came on September 19, 2025, with a stated indication of improving muscle strength in Barth syndrome for patients of at least 30 kg body weight. It relied on an intermediate endpoint, so staying approved depends on confirmatory studies. Every other use is still experimental.
Sources
- Stealth BioTherapeutics Inc. (2025). FORZINITY (elamipretide hydrochloride) injection - prescribing information. DailyMed (U.S. National Library of Medicine).
- U.S. Food and Drug Administration (2025). Drugs@FDA: FORZINITY, NDA 215244. Drugs@FDA.
- Szeto HH (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.. British Journal of Pharmacology.
- Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. Genetics in Medicine.
Read more
For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.